SOUTH EASTON, Mass. — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, pressure cycling technology (“PCT”)-based sample preparation solutions to the worldwide life sciences industry, today announced that it has closed on gross proceeds of $2,180,000 from the initial tranche of a $5 million Private Placement (the “Offering”). Of the amount invested, $1,520,000was received in cash and $660,000 was from the conversion of principal and interest on outstanding promissory notes. One or more additional tranches in the Private Placement may close on or before August 7, 2015.

Pursuant to the Subscription Agreement, the Company will issue Senior Secured Convertible Debentures with a fixed conversion price of $0.28 per restricted common share, and Common Stock Purchase Warrants exercisable into a total of 3,892,857 shares of restricted common stock at an exercise price of $0.40 per share. The Company is under no obligation to file a registration statement to register the shares underlying the Debentures and Warrants.

The Company netted $1,340,000 in cash after taking into account fees related to the Offering and the value of the notes that converted into the Offering.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “The priorities for the use of funds raised in the initial tranche are (i) to increase the number of personnel in our marketing and sales department, to continue building the installed base of instruments and utilization of consumables, and (ii) to retire a significant portion of the variable priced convertible debt we took on to help facilitate growth while additional equity capital was being raised. It is expected that cash received from any additional closings that might occur in the near future will be used to pay off any remaining variable priced convertible debt.”

This press release is not an offer to sell or a solicitation of offers to participate in the Offering. The units, including the shares underlying the Debentures and Warrants, have not been registered under the Securities Act and may not be sold in the United States absent registration under the Securities Act or an applicable exemption from registration.

For more information on the Offering, please see the Form 8k filed by the Company on July 23, 2015.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.